Metabolic syndrome in drug naïve schizophrenic patients

Anjum, Shazia; Bathla, Shalu; Panchal, Saminder; Singh, Gurvinder; Singh, Manpreet

doi:10.1016/j.dsx.2017.11.006

Cited by 24 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 Over 20% of the treatment-naïve schizophrenia patients and first-episode patients were shown to have a lowered HDL-cholesterol level and a glucose dysregulation/insulin resistance. 9,10 It has been suggested that the effects of inflammatory mediators causally contribute to the pathology of schizophrenia and diabetes that accompanies the disorder. 11,12 Several studies had delivered evidence for specific cytokine alterations in different stages of schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

<p>Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia</p>

Boiko¹,

Mednova²,

Kornetova³

et al. 2020

NDT

View full text Add to dashboard Cite

Background: Both dehydroepiandrosterone (DHEAS) and cortisol are secreted by the adrenal glands and may modulate metabolic syndrome (MetS), which often affects the health of patients with schizophrenia. The relationship between the serum levels of these hormones and MetS has not been established. Purpose: In this pilot study, we investigated the serum levels in schizophrenia patients with and without MetS and compared them with those in healthy volunteers. Patients and Methods: After obtaining informed consent, 110 patients with acute paranoid schizophrenia were recruited directly after admission to the Mental Health Research Institute. The control group consisted of 51 persons reported on questioning to be mentally and somatically healthy. Blood samples to prepare serum were drawn after an 8-h overnight fast during one of the first days of admission. Serum cortisol and DHEAS concentrations were quantified by enzyme-linked immunosorbent assay. Results: A total of 42 patients had MetS and 68 patients were without MetS. The cortisol blood level was significantly (p = 0.012) higher in schizophrenia patients without MetS in comparison to healthy controls, while patients with schizophrenia and a MetS have significantly (p = 0.014) lower DHEAS levels than healthy volunteers. These differences could, however, exclusively be attributed to female participants. Analysis of covariance adjusted for gender and age demonstrated a significant relationship between age and DHEAS levels (F = 9.512, р = 0.003). Conclusion: Lower DHEAS serum levels in relationship to MetS become evident in women, but not in men, and have age differences as a confounding factor.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia</p>

Boiko¹,

Mednova²,

Kornetova³

et al. 2020

NDT

View full text Add to dashboard Cite

show abstract

“…Nevertheless, these investigations mainly rely on the post-mortem brains of chronic schizophrenia patients. This constitutes an important limitation, given the long exposure to pharmacological treatment 12 and disease comorbidities (diabetes mellitus type 2, dyslipidemia, obesity) 13 , 14 , which are well-known conditions associated with metabolic profile changes in these patients 15 , 16 . For these reasons, characterizing the profile of amino acids in the peripheral blood of patients in their first-episode psychosis (FEP) can be a reasonable strategy to overcome these caveats, facilitating the comprehension of the pathophysiological processes of psychosis 17 and the tailoring of preventive strategies.…”

Section: Introductionmentioning

confidence: 99%

Plasma amino acids profile in first-episode psychosis, unaffected siblings and community-based controls

Loureiro

Roza

Corsi-Zuelli

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Investigations of plasma amino acids in early psychosis and their unaffected siblings are rare. We measured plasma amino acids involved in the co-activation of dopaminergic, GABAergic, glutamatergic, and serotoninergic neurotransmitters in first-episode psychosis (FEP) patients (n = 166), unaffected siblings (n = 76), and community-based controls (n = 166) included in a cross-sectional study. Plasma levels of glutamic acid (GLU), glutamine, glycine, proline (PRO), tryptophan (TRP), tyrosine, serine and GABA were quantified by gas-chromatography-mass spectrometry. We used the generalized linear model adjusted by sex, age, and body mass index for group comparison and paired t-test for FEP-Sibling pairs. FEP had reduced GABA plasma levels compared to siblings and controls (p < 0.05 for both). Siblings had lower GLU, Glx and PRO (p < 0.05 for all) but increased TRP compared to patients and controls (p < 0.05 for both). FEP patients with longer duration of pharmacological treatment and medicated only with antipsychotics had increased GLU compared to FEP with shorter periods, or with those treated with a combination of medications (p < 0.05 for both). Finally, FEP patients treated only with antipsychotics presented higher Glx compared to those with mixed medications (p = 0.026). Our study suggests that FEP have low a GABA plasma profile. Unaffected siblings may be a possible risk group for metabolic abnormalities.

show abstract

“…Modifiable lifestyle factors seem to contribute largely by affective quality of life, self-esteem, and increasing distress to the occurrence of metabolic syndrome ( 16 ). Some risk factors identified were female gender, antipsychotic use, high BP in men, age > 30 years ( 13 ), fasting blood sugar, and triglycerides ( 18 , 23 ).…”

Section: Resultsmentioning

confidence: 99%

Cardiovascular Diseases and Schizophrenia in India: Evidence, Gaps, and Way Forward

et al. 2021

View full text Add to dashboard Cite

Background: The importance of physical health among persons with schizophrenia is well-established. Studies from developed and developing countries indicated a strong association between cardiovascular diseases and schizophrenia, while evidence from India is scattered and in its infancy. Hence, the aims of the study were to collate available studies from India on cardiovascular diseases among persons with schizophrenia, identify knowledge gaps and challenges, and discuss recommendations to improve clinical care and research on cardiovascular diseases among persons with schizophrenia in India.Materials and methods: A comprehensive literature review of Indian studies on cardiovascular diseases and schizophrenia was conducted to collate and synthesise available knowledge.Results: Several risk factors for cardiovascular disease predominated among persons with schizophrenia. Metabolic syndrome and obesity were the key factors that were reported. Knowledge gaps were identified with respect to the prevalence of cardiovascular diseases among persons with schizophrenia. Sparse research in interventions to prevent and reduce the impact of cardiovascular diseases among persons with schizophrenia was noted.Conclusion: Targeted efforts are needed at the clinic, community, and policy levels to understand the impact of cardiovascular diseases among persons with schizophrenia. Robust and feasible interventions targeting cardiovascular diseases and its varied risk factors in persons with schizophrenia, that can be implemented in tertiary mental health services, need to be developed and tested.

show abstract

Metabolic syndrome in drug naïve schizophrenic patients

Cited by 24 publications

References 29 publications

<p>Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia</p>

<p>Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia</p>

Plasma amino acids profile in first-episode psychosis, unaffected siblings and community-based controls

Cardiovascular Diseases and Schizophrenia in India: Evidence, Gaps, and Way Forward

Contact Info

Product

Resources

About